fluorouracil has been researched along with Diathesis in 6 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data were collected from 1097 consecutive anthracycline-naive patients treated for metastatic breast cancer with epirubicin." | 7.74 | New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. ( Andersen, PK; Cortese, G; Nielsen, D; Nielsen, G; Ryberg, M; Skovsgaard, T, 2008) |
| "Data were collected from 1097 consecutive anthracycline-naive patients treated for metastatic breast cancer with epirubicin." | 3.74 | New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. ( Andersen, PK; Cortese, G; Nielsen, D; Nielsen, G; Ryberg, M; Skovsgaard, T, 2008) |
| "Many trials of anticancer agents have been conducted, excluding patients with heart diseases." | 2.66 | Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. ( Hiraide, M; Shiga, T, 2020) |
| "The median age at diagnosis of colorectal cancer is during the seventh decade, and the incidence of the disease increases continuously with age." | 2.45 | Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use. ( Belda, C; Casado, E; Castro, JD; Feliu, J; González-Barón, M; Sereno, M, 2009) |
| " Susceptibility to motion sickness appears to be a determinant of the side effects of cancer chemotherapy that may prove useful as a clinical marker of those patients who may require more intensive side effect management." | 1.27 | The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. ( Morrow, GR, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Shiga, T | 1 |
| Hiraide, M | 1 |
| Ryberg, M | 1 |
| Nielsen, D | 1 |
| Cortese, G | 1 |
| Nielsen, G | 1 |
| Skovsgaard, T | 1 |
| Andersen, PK | 1 |
| Feliu, J | 1 |
| Sereno, M | 1 |
| Castro, JD | 1 |
| Belda, C | 1 |
| Casado, E | 1 |
| González-Barón, M | 1 |
| El Amrani, M | 1 |
| Aidi, S | 1 |
| Amarenco, P | 1 |
| Itoh, N | 1 |
| Nishimura, H | 1 |
| Matsuguchi, T | 1 |
| Yajima, T | 1 |
| Mokuno, Y | 1 |
| Hiromatsu, T | 1 |
| Nimura, Y | 1 |
| Yoshikai, Y | 1 |
| Morrow, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
3 reviews available for fluorouracil and Diathesis
| Article | Year |
|---|---|
Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascula | 2020 |
Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2009 |
[Cerebral ischemic events and anti-cancer therapy].
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Brain Ischemia; Cerebral Hemorrhage; Child; | 2003 |
3 other studies available for fluorouracil and Diathesis
| Article | Year |
|---|---|
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemo | 2008 |
CD8 alpha-deficient mice are highly susceptible to 5-fluorouracil-induced lethality.
Topics: Adoptive Transfer; Animals; Antimetabolites; CD8 Antigens; CD8-Positive T-Lymphocytes; Disease Susce | 2002 |
The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Susceptibilit | 1985 |